Imaging agents useful for identifying AD pathology

US8420052B2 · kind B2 · utility

Assignee

• Siemens Medical Solutions USA, Inc. · US

Inventors

• Hartmuth C. Kolb · El Segundo, US
• Joseph C. Walsh · Santa Monica, US
• Wei Zhang · San Diego, US
• Umesh B. Gangadharmath · Los Angeles, US
• Dhanalakshmi Kasi · Los Angeles, US
• Kai Chen · Rockville, US
• Anjana Sinha · San Diego, US
• Eric Wang · Yonkers, US
• Gang Chen · Sammamish, US
• Peter J. H. Scott · Ypsilanti, US
• Henry Clifton Padgett · Hermosa Beach, US
• Qianwa Liang · La Puente, US
• Zhiyong Gao · Los Angeles, US
• Tieming Zhao · Los Angeles, US
• Chunfang Xia · Los Angeles, US
• Vani P. Mocharla · Los Angeles, US

Key dates

• Filing date: Jul 24, 2009
• Grant date: Apr 16, 2013
• Expiry date: May 11, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.